Inter-Antibody Variability in the Clinical Pharmacokinetics of Monoclonal Antibodies Characterized Using Population Physiologically Based Pharmacokinetic Modeling
Antibodies · 09.07.2024 · 13 (3) · 54
DOI: 10.3390/antib13030054 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antibodies, online erschienen am 09.07.2024. Verfasst von Mokshada Kumar und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, The State University of New York at Buffalo, Buffalo, NY 14214…. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NCI NIH HHS, The Center for Protein Therapeutics, University at Buffalo.
Abstract (Originalsprache)
The objective of this work was to develop a population physiologically based pharmacokinetic (popPBPK) model to characterize the variability in the clinical PK of monoclonal antibodies (mAbs) following intravenous (IV) and subcutaneous (SC) administration. An extensive literature search was conducted and clinical PK data for FDA-approved as well as non-approved mAbs were collected. Training and validation datasets of 44 and 9 mAbs exhibiting linear pharmacokinetics were used for model development. The variability in antibody PK was captured by accounting for different rate constants of pinocytosis (CLup) and intracellular degradation (kdeg) for different mAbs. Typical values for CLup and kdeg and their respective inter-antibody variabilities (ωClup, ωKdeg) were estimated to be 0.32 L/h/L and 26.1 h−1 (73% and 46%). Varied absorption profiles following SC dosing were characterized by incorporating inter-antibody variability in local degradation (kSC) and rate of lymphatic uptake (S_Lu) of mAbs. Estimates for typical kSC and S_Lu values, and ωKsc,ωS_Lu, were found to be 0.0015 h−1 and 0.54 (193%, and 49%). FDA-approved mAbs showed less local degradation (0.0014 h−1 vs. 0.0038 h−1) compared with other clinically tested mAbs, whereas no substantial differences in physiological processes involved in disposition were observed. To evaluate the generalizability of estimated PK parameters and model validation, the final popPBPK model was used to simulate the range of expected PK for mAbs following SC administration of nine different mAbs that were not used for model-building purposes. The predicted PK of all nine mAbs was within the expected range specified a priori. Thus, the popPBPK model presented here may serve as a tool to predict the clinical PK of mAbs with linear disposition before administering them to humans. The model may also support preclinical-to-clinical translation and ‘first-in-human’ dose determination for mAbs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, The State University of New York at Buffalo, Buffalo, NY 14214-8033, USA.
- Enhanced Pharmacodynamics, LLC, Buffalo, NY 14203, USA.
ORCID-Profile: Dhaval K Shah
Förderung
- NIGMS NIH HHS
- NCI NIH HHS
- The Center for Protein Therapeutics, University at Buffalo
- NICHD NIH HHS
- NIAID NIH HHS
- Center for Protein Therapeutics at the University of Buffalo
- National Institute of General Medical Sciences
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Kumar, M., Lanke, S., Yadav, A., Ette, M., Mager, D. E., & Shah, D. K. (2024). Inter-Antibody Variability in the Clinical Pharmacokinetics of Monoclonal Antibodies Characterized Using Population Physiologically Based Pharmacokinetic Modeling. Antibodies, 13(3), 54. https://doi.org/10.3390/antib13030054
Vancouver
Kumar M, Lanke S, Yadav A, Ette M, Mager DE, Shah DK. Inter-Antibody Variability in the Clinical Pharmacokinetics of Monoclonal Antibodies Characterized Using Population Physiologically Based Pharmacokinetic Modeling. Antibodies. 2024;13(3):54. doi:10.3390/antib13030054
BibTeX
@article{Kumar2024,
author = {Kumar, Mokshada and Lanke, Sravani and Yadav, Alka and Ette, Mfonabasi and Mager, Donald E and Shah, Dhaval K},
title = {Inter-Antibody Variability in the Clinical Pharmacokinetics of Monoclonal Antibodies Characterized Using Population Physiologically Based Pharmacokinetic Modeling},
journal = {Antibodies},
year = {2024},
volume = {13},
number = {3},
pages = {54},
doi = {10.3390/antib13030054}
}
EUVIMED